Technology evaluation: Rexin-G, Epeius Biotechnologies.
Rexin-G is a 'pathotropic', tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene, under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. The therapy is currently undergoing phase I/II clinical trials.
Volume / Issue
Start / End Page
Pubmed Central ID
International Standard Serial Number (ISSN)